Newswise — July 11, 2017 ─ Premature babies treated with caffeine have better lung function in mid-childhood than preemies not treated with caffeine, according to a randomized controlled trial published in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
“Previous studies have shown that caffeine, which belongs to a group of drugs known as methylxanthines, reduces apnea of prematurity, a condition in which the baby stops breathing for many seconds,” said lead study author Lex W. Doyle, MD, professor of neonatal pediatrics at the Royal Women’s Hospital in Melbourne and head of the Australian National Health and Medical Research Council’s Centre of Research Excellence in Newborn Medicine.
Dr. Doyle added that caffeine, one of the most widely used drugs in neonatal intensive care, shortens the time premature infants require help breathing after birth. It also reduces the chances that the newborn will develop lung injury or abnormal lung development, a condition called bronchopulmonary dysplasia, which can lead to higher rates of breathing problems later in life.
In “Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children ,” Dr. Doyle and colleagues report on their study to determine if the lung benefits of caffeine in premature babies persist in mid-childhood.
At age 11, 142 children living in Australia who had been part of the international Caffeine for Apnea of Prematurity randomized controlled trial had their expiratory flow rates measured. Slightly more than half the children had been enrolled in the caffeine intervention; the others had been given a placebo.
The researchers found expiratory flows were significantly better in the caffeine group by approximately one-half a standard deviation for FEV1 (the maximum amount of air that can be forcefully blown out in one second), FVC (the amount of air that can be forcibly exhaled after taking the deepest breath possible) and FEF25-75% (the average flow from the point at which 25 percent of the FVC has been exhaled to the point at which 75 percent of the FVC has been exhaled.) FEV1/FVC (a measure of obstructive lung disease) was better by a lesser amount but still statistically significant.
The researchers said that caffeine appeared to improve long-term breathing by reducing lung injury and abnormal development during the newborn period, “rather than the caffeine molecule having any direct effect on the lung itself.”
Study limitations include the fact that respiratory function tests measured only expiratory flows and the children were from only one of the Caffeine for the Apnea of Prematurity trial sites.
“It would be desirable to repeat lung function more extensively later in life, and at more sites to identify those participants at highest risk of developing severe breathing disorders in adulthood,” Dr. Doyle said. “If it were possible to repeat lung function at one time only, the best time would be around age 25, when lung growth peaks.”
This study was funded by the National Health and Medical Research Council of Australia, the Centre of Clinical Research Excellence, the Centre of Research Excellence and the Victorian Government’s Operational Infrastructure Support Program.
Contact for Article
Lex W. Doyle, MD
Email: [email protected]
Phone: +613 83453716
Share via Twitter
“#Preemies with inadequate #lung function that were treated with caffeine have better lung function 11 years later.”
ATS - @atscommunity
AJRCCM - @ATSBlueEditor
About the American Journal of Respiratory and Critical Care Medicine (AJRCCM):
The AJRCCM is a peer-reviewed journal published by the American Thoracic Society. The Journal takes pride in publishing the most innovative science and the highest quality reviews, practice guidelines and statements in pulmonary, critical care and sleep medicine. With an impact factor of 12.996, it is the highest ranked journal in pulmonology. Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.
About the American Thoracic Society:
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society
The ATS will hold its 2018 International Conference, May 18-23, in San Diego, California, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.
MEDIA CONTACTRegister for reporter access to contact details